Combined with several molecules have been successfully applied in preclinical cancer models23, 24, 25, 26 and are likely to be taken forward to clinical trails, the present data suggest that pharmacological inhibition of EZH2 enzymatic activity could provide a basis of for its use as a therapeutic intervention in non-Hodgkin lymphoma and solid tumors, which are dependent on EZH2 enzymatic activity and ZLD1039 is worth being optimized and develop as a therapeutic agent for clinical application. This evidence concerns the gene EZH2 and non-Hodgkin lymphoma.